Wall Street Zen Upgrades Teleflex (NYSE:TFX) to "Buy"

Teleflex (NYSE:TFX - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

Other research analysts also recently issued reports about the stock. Morgan Stanley dropped their target price on shares of Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a research report on Monday, May 5th. Wells Fargo & Company lowered their price objective on shares of Teleflex from $146.00 to $137.00 and set an "equal weight" rating on the stock in a research report on Friday, May 2nd. Piper Sandler reissued a "neutral" rating and set a $140.00 price objective (down from $255.00) on shares of Teleflex in a research report on Friday, February 28th. Raymond James Financial downgraded shares of Teleflex from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Mizuho set a $155.00 price objective on shares of Teleflex in a research report on Wednesday, April 16th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $164.63.

Teleflex Trading Up 0.3%

NYSE TFX opened at $118.03 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.28 and a quick ratio of 1.32. The firm's fifty day moving average price is $125.44 and its 200 day moving average price is $150.14. The company has a market capitalization of $5.22 billion, a price-to-earnings ratio of 37.23, a price-to-earnings-growth ratio of 1.84 and a beta of 1.10. Teleflex has a 12 month low of $116.60 and a 12 month high of $249.91.

Teleflex (NYSE:TFX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, beating analysts' consensus estimates of $2.88 by $0.03. The firm had revenue of $700.67 million for the quarter, compared to the consensus estimate of $699.37 million. Teleflex had a net margin of 4.96% and a return on equity of 14.73%. The company's revenue was down 5.0% on a year-over-year basis. During the same period last year, the firm posted $3.21 EPS. On average, sell-side analysts expect that Teleflex will post 13.98 earnings per share for the current fiscal year.

Institutional Trading of Teleflex

Several hedge funds have recently made changes to their positions in the company. Strs Ohio acquired a new stake in shares of Teleflex in the 1st quarter worth $3,040,000. IFM Investors Pty Ltd lifted its stake in shares of Teleflex by 7.8% in the 1st quarter. IFM Investors Pty Ltd now owns 8,311 shares of the medical technology company's stock worth $1,148,000 after acquiring an additional 602 shares during the period. Jane Street Group LLC lifted its stake in shares of Teleflex by 42.6% in the 1st quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company's stock worth $877,000 after acquiring an additional 1,895 shares during the period. Empowered Funds LLC lifted its stake in shares of Teleflex by 15.8% in the 1st quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company's stock worth $233,000 after acquiring an additional 230 shares during the period. Finally, United Services Automobile Association acquired a new stake in shares of Teleflex in the 1st quarter worth $373,000. Institutional investors and hedge funds own 95.62% of the company's stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.